The Conversation (0)
RespireRx Pharmaceuticals Inc. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
Jul. 13, 2016 07:44AM PST
Life Science Investing News
RespireRx Pharmaceuticals Inc. (OTCQB:RSPI), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference (www.cantor.com) in New York, New York on Wednesday, July 13, 2016, at 9:30 a.m. Eastern Time.
RespireRx Pharmaceuticals Inc. (OTCQB:RSPI), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference (www.cantor.com) in New York, New York on Wednesday, July 13, 2016, at 9:30 a.m. Eastern Time. The Conference is being sponsored by Cantor Fitzgerald & Co. and is being held at Le Parker Meridien Hotel, New York, New York, on July 12 and July 13, 2016.
RespireRx Pharmaceuticals President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D, stated:
The presentation at the Cantor Fitzgerald Conference will provide RespireRx management with the opportunity to give investors an update on RespireRx’s strategic initiatives and progress on research and development programs. I look forward to discussing the Company’s Phase 2A clinical trial testing the impact of the oral ampakine, CX-1739, on opioid-induced respiratory depression.
We are pleased to keep our shareholders and other stakeholders informed as to the continuing progress of RespireRx’s scientific, clinical and regulatory development initiatives.